Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
3
×
detroit top stories
fda
3
×
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
3
×
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
3
×
wisconsin blog main
wisconsin top stories
biotech
clinical trials
drugs
eli lilly
indiana blog main
indiana top stories
jefferies
advaxis
age related macular degeneration
agios pharmaceuticals
aimmune therapeutics
alder biopharmaceutical
alder biopharmaceuticals
alexander hardy
allergan
What
big
3
×
meeting
week
american
approval
arguments
ash
bio
blood
bosley's
bosley’s
bridge
bucks
cas
ceo
class
commercialized
companies
competitors
country
crime
crispr
decades
departure
diego
disease
drug
drugs
editas
exit
fda
gathering
guiding
hematology’s
katrine
largest
make
medical
medicine
migraine
Language
Current search:
big
×
fda
×
" texas top stories "
×
" detroit blog main "
×
" raleigh-durham blog main "
×
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com
5 years ago
ASH 2018: Three Up, Two Down As The Big Blood Disease Meeting Rolls On